Dallas, TX (PRWEB) July 29, 2015
The report “Atherosclerosis - Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclerosis-pipeline-review-h1-2015-market-report.html .
Companies discussed in this Atherosclerosis - Pipeline Review, H1 2015 report include Ache Laboratorios Farmaceuticos, advanceCor GmbH, AFFiRiS AG, Arisaph Pharmaceuticals, Inc., Artery Therapeutics, Inc., AstraZeneca Plc, Athera Biotechnologies AB, AtheroNova Inc., AuraSense Therapeutics, LLC, Bayer AG, Bridge Bioresearch Plc, Campus Technologies Freiburg G, Cardax Pharmaceuticals, Inc., ChemoCentryx, Inc., CohBar Inc., DoNatur GmbH, Dr. Reddy's Laboratories Limited, Dybly AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GenKyoTex S.A., Gilead Sciences, Inc., Isis Pharmaceuticals, Inc., Jenrin Discovery, Inc., Johnson & Johnson, KineMed, Inc., Kowa Company, Ltd., Lead Discovery Center GmbH, MedImmune, LLC, Merck & Co., Inc., MI.TO. Technology S.r.L., Novartis AG, Omeros Corporation, OPKO Health, Inc., Otsuka Holdings Co., Ltd., Provid Pharmaceuticals, Inc., Resverlogix Corp., The Medicines Company, Therapix Biosciences Ltd, Vascular Biogenics Ltd., Vericel Corporation, Vitae Pharmaceuticals, Inc.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Drug Profiles mentioned in this report are 6860766, AEM-28, AG-01, AHRO-001, AHRO-002, AHRO-003, aliskiren fumarate, AM-0010, anacetrapib, Annexin A-5, Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis, ARI-1778, Artpep-2, ATH-03, ATH-04, ATH-05, ATH-06, AZ-876, BAY-606583, BSN-272, CCX-771, CCX-872, CDX-085, Cell Therapy for Atherosclerosis, CM-7, COR-2, CSN-501, CVX-210H, D-4F, DIAS-2, DRL-17822, Drug for Atherosclerosis, Drug to Agonize TLR-4 for Metabolic Disorders, Immunology and Cardiovascular Disease, Drugs for Cardiovascular Diseases, Drugs to Activate TLR3 for Atherosclerosis, Drugs to Antagonize NMDA Receptor for Atherosclerosis, DYB-186, EP-80317, evacetrapibFX-5A, Gene Therapy for Arteriosclerosis and Endothelial Dysfunction, Gene Therapy to Activate Interleukin 10 for Atherosclerosis, Gene Therapy to Target miR-145 for Atherosclerosis, GKT-136901, GKT-137831, GKT-901, GYY-4137, Humanin, INV-88, ISIS-APOARx, ixmyelocel-T, JD-6000 Series, K-312, K-877, KM-011, KRP-206, LDN-193189, LPC-01, MCS-18, MDCO-216, MEDI-6012, Small Molecule to Target GPR132 for Atherosclerosis, Small Molecules for Atherosclerosis, Small Molecules for Atherosclerosis, SPX-7233801, Stem Cell Therapy for Atherosclerosis, SYN-20110119RU, VB-201, VTP-4.
Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=397254 . (This is a premium report priced at US$2000 for a single user License.)
Partial List of Tables
Number of Products under Development for Atherosclerosis, H1 2015 19
Number of Products under Development for Atherosclerosis - Comparative Analysis, H1 2015 20
Number of Products under Development by Companies, H1 2015 22
Number of Products under Development by Companies, H1 2015 (Contd..1) 23
Number of Products under Development by Companies, H1 2015 (Contd..2) 24
Number of Products under Development by Companies, H1 2015 (Contd..3) 25
Number of Products under Investigation by Universities/Institutes, H1 2015 27
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 28
Comparative Analysis by Late Stage Development, H1 2015 29
Comparative Analysis by Clinical Stage Development, H1 2015 30
Comparative Analysis by Early Stage Development, H1 2015 31
Products under Development by Companies, H1 2015 32
Products under Development by Companies, H1 2015 (Contd..1) 33
Products under Development by Companies, H1 2015 (Contd..2) 34
Products under Development by Companies, H1 2015 (Contd..3) 35
Products under Development by Companies, H1 2015 (Contd..4) 36
Products under Investigation by Universities/Institutes, H1 2015 37
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 38
Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2015 39
Atherosclerosis - Pipeline by advanceCor GmbH, H1 2015 40
Atherosclerosis - Pipeline by AFFiRiS AG, H1 2015 41
Atherosclerosis - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2015 42
Atherosclerosis - Pipeline by Artery Therapeutics, Inc., H1 2015 43
Atherosclerosis - Pipeline by AstraZeneca Plc, H1 2015 44
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2015 45
Atherosclerosis - Pipeline by AtheroNova Inc., H1 2015 46
Atherosclerosis - Pipeline by AuraSense Therapeutics, LLC, H1 2015 47
Atherosclerosis - Pipeline by Bayer AG, H1 2015 48
Atherosclerosis - Pipeline by Bridge Bioresearch Plc, H1 2015 49
Atherosclerosis - Pipeline by Campus Technologies Freiburg GmbH, H1 2015 50
Explore more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Read the full story at http://www.prweb.com/releases/atherosclerosis-pipeline/review-h1-2015-market/prweb12875944.htm.
Copyright©2015 Vocus, Inc.
All rights reserved